Topic Intelligence
Articles and insights tagged Cannabidiol (CBD) on FAQSIR.
Following the U.S. Department of Justice's reclassification of certain marijuana products, WEED Inc. (OTCQB:BUDZ) discusses the implications for its legacy genetics portfolio.
WEED Inc. is evaluating strategic options involving its Sugar Hill asset and corporate initiatives to maximize shareholder returns, signaling potential developmental opportunities.
1933 Industries Inc. announced its financial results for the second quarter of fiscal 2026, noting revenue decline and resilience in its product offerings.
CV Sciences, Inc. has released its financial results for fiscal year 2025, showing a decline in revenue, enhanced gross margins, and a strategic focus on operational efficiency.
Zoned Properties is initiating a complete liquidation of its assets and operations, establishing plans to maximize returns for shareholders.
1933 Industries reports a net income of $139,219 for Q1 2026, along with a substantial reduction in expenses, signaling operational improvements as the cannabis market evolves.
CV Sciences, Inc. posted a revenue decline in Q3 2025, driven largely by lower sales volume. Despite this, the company remains focused on innovation and regulatory collaboration.
Charlie's Holdings has announced the discontinuation of its hemp and CBD product sales, alongside the closure of its Don Polly division, as part of a strategic move to enhance stock liquidity and prepare for an uplisting.
The enhanced partnership between Ovation Science and Skinvisible Pharmaceuticals aims to leverage innovative cannabinoid delivery technology for obesity treatments, addressing significant market needs and offering promising therapeutic options.